{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:30:56Z","timestamp":1792812656495,"version":"4.5.0"},"reference-count":36,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","award":["59876239"],"award-info":[{"award-number":["59876239"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bayer"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003Current guidelines recommend either low-molecular weight heparin (LMWH) or direct oral anticoagulants (DOACs) as first-line treatment in cancer-associated venous thromboembolism (VTE).<\/jats:p><jats:p>\n          Aim\u2003This study aimed to investigate treatment regimens for cancer-associated VTE over the past 5 years, explore predictors for initial treatment (LMWH vs. DOAC), and to assess the risks of recurrent VTE and bleeding.<\/jats:p><jats:p>\n          Methods\u2003This was a Dutch, multicenter, retrospective cohort study including consecutive patients with cancer-associated VTE between 2017 and 2021. Treatment predictors were assessed with multivariable logistic regression models. Six-month cumulative incidences for recurrent VTE and major bleeding (MB) were estimated with death as competing risk.<\/jats:p><jats:p>\n          Results\u2003In total, 1,215 patients were included. The majority (1,134\/1,192; 95%) started VTE treatment with anticoagulation: 561 LMWH (47%), 510 DOACs (43%), 27 vitamin K antagonist (2.3%), and 36 other\/unknown type (3.0%). The proportion of patients primarily treated with DOACs increased from 18% (95% confidence interval [CI] 12\u201325) in 2017 to 70% (95% CI 62\u201378) in 2021. Poor performance status (adjusted odds ratio [aOR] 0.72, 95% CI 0.53\u20130.99) and distant metastases (aOR 0.61, 95% CI 0.45\u20130.82) were associated with primary treatment with LMWH. Total 6-month cumulative incidences were 6.0% (95% CI 4.8\u20137.5) for recurrent VTE and 7.0% (95% CI 5.7\u20138.6) for MB. During follow-up, 182 patients (15%) switched from LMWH to a DOAC, and 54 patients (4.4%) vice versa, for various reasons, including patient preference, recurrent thrombosis, and\/or bleeding.<\/jats:p><jats:p>\n          Conclusion\u2003DOAC use in cancer-associated VTE has increased rapidly over the past years. Changes in anticoagulation regimen were frequent over time, and were often related to recurrent thrombotic and bleeding complications, illustrating the complexity and challenges of managing cancer-associated VTE.<\/jats:p>","DOI":"10.1055\/a-2214-8101","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:04:15Z","timestamp":1700611455000},"page":"e61-e71","source":"Crossref","is-referenced-by-count":1,"title":["Treatment Patterns of Cancer-associated Thrombosis in the Netherlands: The Four Cities Study"],"prefix":"10.1055","volume":"08","author":[{"given":"Fleur H.J.","family":"Kaptein","sequence":"additional","affiliation":[{"name":"Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1426-3170","authenticated-orcid":false,"given":"Noori A.M.","family":"Guman","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, the Netherlands"},{"name":"Department of Pulmonary Hypertension and Thrombosis, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands"},{"name":"Department of Internal Medicine, Tergooi Medical Center, Hilversum, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan B.","family":"Lohle","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, the Netherlands"},{"name":"Department of Pulmonary Hypertension and Thrombosis, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9961-0754","authenticated-orcid":false,"given":"Frederikus A.","family":"Klok","sequence":"additional","affiliation":[{"name":"Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert T.A.","family":"Mairuhu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Haga Hospital, The Hague, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter W.","family":"Kamphuisen","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, the Netherlands"},{"name":"Department of Pulmonary Hypertension and Thrombosis, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands"},{"name":"Department of Internal Medicine, Tergooi Medical Center, Hilversum, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick Van","family":"Es","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, the Netherlands"},{"name":"Department of Pulmonary Hypertension and Thrombosis, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno V.","family":"Huisman","sequence":"additional","affiliation":[{"name":"Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"P Prandoni","year":"2002","journal-title":"Blood"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1160\/TH15-08-0686","article-title":"Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study","volume":"117","author":"A T Cohen","year":"2017","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"A YY Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"A A Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"20","key":"ref5","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"A M Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial","volume":"18","author":"R D McBane II","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"G E Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"ref8","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"G Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"G H Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"09","key":"ref10","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"A A Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"D Farge","year":"2019","journal-title":"Lancet Oncol"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST Guideline and expert panel report","volume":"160","author":"S M Stevens","year":"2021","journal-title":"Chest"},{"issue":"29","key":"ref14","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thromboembolism in the patient with cancer","volume":"27","author":"A A Khorana","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.thromres.2021.08.002","article-title":"Incidence, timing and risk factors of venous thromboembolic events in patients with pancreatic cancer","volume":"207","author":"R G Hanna-Sawires","year":"2021","journal-title":"Thromb Res"},{"issue":"09","key":"ref16","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/jth.13403","article-title":"Current and future perspectives in imaging of venous thromboembolism","volume":"14","author":"C EA Dronkers","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/jth.12124","article-title":"Diagnostic management of acute deep vein thrombosis and pulmonary embolism","volume":"11","author":"M V Huisman","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"18028","DOI":"10.1038\/nrdp.2018.28","article-title":"Pulmonary embolism","volume":"4","author":"M V Huisman","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jclinepi.2020.11.014","article-title":"Text-mining in electronic healthcare records can be used as efficient tool for screening and data collection in cardiovascular trials: a multicenter validation study","volume":"132","author":"W B van Dijk","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","article-title":"Competing risk analysis using R: an easy guide for clinicians","volume":"40","author":"L Scrucca","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1076029620975489","DOI":"10.1177\/1076029620975489","article-title":"Retrospective review of prescribing patterns in cancer-associated thrombosis: a single center experience in Edmonton, Alberta, Canada","volume":"27","author":"H Kaliel","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/ajh.25604","article-title":"Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism","volume":"94","author":"W E Wysokinski","year":"2019","journal-title":"Am J Hematol"},{"issue":"09","key":"ref23","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.amjmed.2018.04.037","article-title":"Arterial ischemic events are a major complication in cancer patients with venous thromboembolism","volume":"131","author":"B Brenner","year":"2018","journal-title":"Am J Med"},{"issue":"08","key":"ref24","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"B B Navi","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"ref25","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood-2014-01-549733","article-title":"Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study","volume":"123","author":"C E Chee","year":"2014","journal-title":"Blood"},{"issue":"08","key":"ref26","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.jtha.2023.04.010","article-title":"Predictors of recurrence of cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a multicenter cohort study","volume":"21","author":"F-X Lap\u00e9bie","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref27","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3324\/haematol.2018.192419","article-title":"Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer","volume":"103","author":"E Grilz","year":"2018","journal-title":"Haematologica"},{"issue":"02","key":"ref28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaccao.2021.03.001","article-title":"Venous and arterial thromboembolism in patients with cancer: JACC: CardioOncology State-of-the-Art Review","volume":"3","author":"L Gervaso","year":"2021","journal-title":"JACC Cardiooncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.lungcan.2021.05.019","article-title":"Thromboembolism in ALK+ and ROS1+ NSCLC patients: a systematic review and meta-analysis","volume":"157","author":"V W Zhu","year":"2021","journal-title":"Lung Cancer"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2016.07.013","article-title":"Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed?","volume":"145","author":"A A Khorana","year":"2016","journal-title":"Thromb Res"},{"issue":"08","key":"ref31","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1253\/circj.CJ-20-0084","article-title":"Direct oral anticoagulant therapy for cancer-associated venous thromboembolism in routine clinical practice","volume":"84","author":"Y Ogino","year":"2020","journal-title":"Circ J"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/rth2.12002","article-title":"Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis","volume":"1","author":"A A Khorana","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"47","key":"ref33","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1093\/eurheartj\/ehac587","article-title":"Bleeding and ischaemic events after first bleed in anticoagulated atrial fibrillation patients: risk and timing","volume":"43","author":"P B Meyre","year":"2022","journal-title":"Eur Heart J"},{"issue":"05","key":"ref34","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jtha.2023.02.015","article-title":"Outcomes of venous thromboembolism care: future directions","volume":"21","author":"C MM de Jong","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref35","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/jth.15666","article-title":"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up","volume":"20","author":"T-L Larsen","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref36","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1055\/a-1647-9896","article-title":"Extended anticoagulant treatment with full- or reduced-dose apixaban in patients with cancer-associated venous thromboembolism: rationale and design of the API-CAT Study","volume":"122","author":"I Mah\u00e9","year":"2022","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/ejh.13338","article-title":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial","volume":"104","author":"R D McBane II","year":"2020","journal-title":"Eur J Haematol"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2214-8101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:12:06Z","timestamp":1730812326000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2214-8101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":36,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2024,1,8]]},"published-print":{"date-parts":[[2024,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2214-8101","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"value":"2512-9465","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,21]]},"published":{"date-parts":[[2023,11,21]]}}}